Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen K Chia

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Breast Cancer Research and Treatment|February 12, 2009
Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patientsShuzhen Liu, Stephen K Chia, Erika Mehl, et al.
Investigational New Drugs|July 14, 2005
A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancerKim N Chi, Stephen K Chia, Ross Dixon, et al.
Clinical Breast Cancer|July 8, 2019
Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional DatabaseNathalie LeVasseur, Kaylie-Anne Willemsma, Huaqi Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotypeMaggie C U Cheang, David Voduc, Chris Bajdik, et al.
Clinical Breast Cancer|October 25, 2021
Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility StudyNathalie LeVasseur, Julia Sun, David Fenton, et al.
Clinical Breast Cancer|July 25, 2008
Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancerSimon J Crabb, Maggie C U Cheang, Samuel Leung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2017
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2<sup>+</sup>-Advanced Solid Tumors, with an Expansion Cohort in HER2<sup>+</sup> Metastatic Breast Cancer (MBC)Stacy L Moulder, Virginia F Borges, Tara Baetz, et al.
Cancer|February 21, 2008
Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifenHagen Kennecke, Heather McArthur, Ivo A Olivotto, et al.
Cancer|July 25, 2007
The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancerStephen K Chia, Caroline H Speers, Yulia D'yachkova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Population-based validation of the prognostic model ADJUVANT! for early breast cancerIvo A Olivotto, Chris D Bajdik, Peter M Ravdin, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Breast Cancer Research and Treatment|February 12, 2009
Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patientsShuzhen Liu, Stephen K Chia, Erika Mehl, et al.
Investigational New Drugs|July 14, 2005
A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancerKim N Chi, Stephen K Chia, Ross Dixon, et al.
Clinical Breast Cancer|July 8, 2019
Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional DatabaseNathalie LeVasseur, Kaylie-Anne Willemsma, Huaqi Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotypeMaggie C U Cheang, David Voduc, Chris Bajdik, et al.
Clinical Breast Cancer|October 25, 2021
Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility StudyNathalie LeVasseur, Julia Sun, David Fenton, et al.
Clinical Breast Cancer|July 25, 2008
Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancerSimon J Crabb, Maggie C U Cheang, Samuel Leung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2017
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2<sup>+</sup>-Advanced Solid Tumors, with an Expansion Cohort in HER2<sup>+</sup> Metastatic Breast Cancer (MBC)Stacy L Moulder, Virginia F Borges, Tara Baetz, et al.
Cancer|February 21, 2008
Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifenHagen Kennecke, Heather McArthur, Ivo A Olivotto, et al.
Cancer|July 25, 2007
The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancerStephen K Chia, Caroline H Speers, Yulia D'yachkova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Population-based validation of the prognostic model ADJUVANT! for early breast cancerIvo A Olivotto, Chris D Bajdik, Peter M Ravdin, et al.
Pageof 4